Endocrine therapy for breast cancer

Breast cancer endocrine therapy is a selective earliest successful examples of targeted therapy.

Situation from the receptors, estrogen and progesterone receptor-positive patients with the best results. As reported in the literature abroad, first-line endocrine therapy for breast cancer, estrogen receptor (+) and progesterone receptor (+) were effective up to 60%, estrogen receptor (+) and progesterone receptor (-) or estrogen receptor (-) progesterone receptor (+) of efficiency was 20-30%, while estrogen receptor (-) progesterone receptor (-) those who have efficiency of about 5%. Is generally believed that, for estrogen or progesterone receptor-positive patients, regardless of their age, menstrual status, tumor size, lymph node whether the transfer, shall be subject to endocrine therapy.

From the stages of treatment point of view, Furlong can be used for second-line rescue, line rescue, and the neo-adjuvant phase.

1, second-line rescue. Recurrence after the transfer, used chemotherapy or other endocrine therapy, but the disease still progress in treatment failure of patients need second-line rescue. To Femara for the treatment of drug use AR/BC2 test in 10 countries, 91 hospitals completed the 551 cases of patients with the treatment of postmenopausal women with advanced, effective for 23.6%, benefiting from rate was 33.3%, overall assessment of efficacy Amino-derivative can be better than sleep. AR/BC3 another large-scale international multi-center trial in 11 countries, 86 hospitals in 444 postmenopausal patients with advanced, efficient and effective for 19.5%, benefiting from rate was 36.6 percent, more effective than A in pregnancy ketone.

Second, front-line rescue. The most influential, the most important test is to rescue the 025 first-line test. The trial in 29 countries, 201 hospitals, 910 cases of recurrence and metastasis in patients with treatment efficiency of 30.2%, benefiting from rate was 48.8 percent, more effective than tamoxifen, because these patients are metastasis and recurrence after outset furlong, so more effective than second-line rescue the AR/BC2 and AR/BC3 test patients.

Third, the new adjuvant therapy. Neo-adjuvant treatment of 024 trials in 16 countries, 55 hospitals have treated 324 cases of pre-operative patients. After treatment, these patients through clinical medical checkup, efficiency of 55%, by ultrasound and X-ray examination, efficiency of 34% -35%. These were neo-adjuvant treatment of patients, application of anti-cancer treatment Femara is the first time, that is really the first time receiving breast cancer treatment, so the effect off than first-line rescue treatment better, the overall effect is also better than tamoxifen.

Fourth, strengthen the adjuvant therapy. Application of tamoxifen treatment after surgery, after five years continue to strengthen its taking Femara for five years can reduce the risk of recurrence of breast cancer in 43% and 50% of the contralateral breast cancer occurrence, and can significantly improve disease-free survival.